TITLE

Patient Profiles in Psoriatic Disease: A Case-Based Approach

PUB. DATE
October 2007
SOURCE
Dermatology Nursing;Oct2007 Supplement, Vol. 19, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a study that describes the basic characteristics of psoriatic disease, a dermatologic disorder that affects residents in the U.S. It discusses the need for appropriate management for early and aggressive intervention of this condition. It highlights the principles that maximizes treatment outcomes by giving tumor necrosis factor-alpha antagonist therapy.
ACCESSION #
27464384

 

Related Articles

  • Biologics. Jesitus, John // Dermatology Times;Apr2009 Supplement, Vol. 40, p10 

    The article focuses on increasing long-term data on existing biologic drugs for psoriasis. These include a study about the low mortality risk of rheumatoid arthritis (RA) patient who is taking tumor necrosis factor (TNF) blocker. Moreover, common developments for psoriasis drugs are also...

  • Safety of Etanercept in Psoriasis: A Critical Review. Carazo, Jose L. Sánchez; Santos, Laura Mahiques; Martinez, Vicente Oliver // Drug Safety;2006, Vol. 29 Issue 8, p675 

    Conventional systemic treatments for patients with psoriasis are associated with multiple adverse effects that require continuous monitoring. The introduction of new biological agents such as etanercept, a fully human fusion protein, has permitted individualisation of patients’...

  • Treating Itch in Psoriasis. Dawn, Aerlyn; Yosipovitch, Gil // Dermatology Nursing;Jun2006, Vol. 18 Issue 3, p227 

    The article presents a study on the effective management and treatment of psoriatic itch. Patients with chronic pruritus often have difficulty sleeping, problems concentrating, lowered sex drive, and depression. The treatments recommended for psoriatic itch are tar products, topical...

  • tazarotene.  // Royal Society of Medicine: Medicines;2002, p523 

    The article presents information on tazarotene which is chemically a derivative of retinol or vitamin A. This drug can be used to treat mild to moderate plaque psoriasis. Administration is by topical application. It should not be used in pregnancy or breast-feeding. Patients should wash hands...

  • New oral psoriasis agents show promise. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS13 

    Introduces different oral treatment for psoriasis. Side effects of the retinoid, an oral tazarotene; Acquisition of a new oral formulation of the drug BG-12 oral fumarate by Biogen; Discussion on the effects of oral pimecrolimus on psoriatic patients.

  • Biologies for psoriasis pulling their weight. Wilson, Fred // Dermatology Times;Sep2004 Supplement, Vol. 25, pS18 

    The article discusses the effect of biologic therapy on psoriatic patients. Consideration of Amevive as the first biologic drug approved for moderate to severe plaque psoriasis; Elaboration on the effects of the drug, Raptiva; Responses of patients to Remicade infusions.

  • Easing trepidation about biologies. Kapes, Beth // Dermatology Times;Sep2004 Supplement, Vol. 25, pS27 

    Discusses the benefits offered by biologics for psoriasis treatment. Affirmation of David E. Cohen that the new biologic products offer advantages over existing medications; Presentation of new biologics that are approved for treating moderate to sever psoriasis and psoriatic arthritis;...

  • Physician says TNF-a antagonists very safe, overall. Guttman, Cheryl // Dermatology Times;Sep2004 Supplement, Vol. 25, pS33 

    Reports that TNF-a antagonists are safe for psoriatic patients. Presentation of several antagonists safe for psoriatic therapy; Discussion on the risks of serious infections and malignancies related to the immunosuppressive activity of the TNF-a antagonist; Effects on patients after treated with...

  • Study shows leading drugs' effectiveness against psoriasis. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS34 

    The article discusses the effectiveness of leading drugs against psoriasis. Statement of Craig L. Leonardi, associate dermatologist of St. Louis University in Missouri, on the effectiveness of Biogen's alefacept; Clarifications on the length of effectiveness of some drugs; Discussion on the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics